Mi-Young Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mi-Young Kim has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Sang-Woon Choi
Chaum Life Center, CHA University School of Medicine, Seoul, South Korea
2 shared publications - Annie J. Kruger
Liver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
1 shared publication - Baek Hwan Cho
Department of Biomedical Informatics, CHA University School of Medicine, CHA University, Seongnam, Republic of Korea
1 shared publication - Daeun Kim
Department of Biological Sciences, College of Natural Sciences and Department of Molecular Science and Technology, Ajou University, Suwon, Republic of Korea
1 shared publication - Donghoon Choi
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
1 shared publication - Eun Young Kim
Graduate School of Medicine, CHA University, Seongnam, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 13 September 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 229, 115786
Immune-enhanced machine learning approach for early detection of precancerous colorectal neoplasia: Insights from biomarkers in routine health checkups
- 13 September 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 229, 115786
Open AccessImmune-enhanced machine learning approach for early detection of precancerous colorectal neoplasia: Insights from biomarkers in routine health checkups
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 4199
Abstract 4199: rhIL-7-hyFc (efineptakinalpha; NT-I7) enhances the anti-tumor response when combined with hIL-2/TCB2c complex
RhIL-7-hyFc (efineptakin-alfa; NT-I7) is a potent T cell amplifier, with a homodimeric interleukin-7 (IL-7) fused to the hybridizing IgD/IgG4 immunoglobulin domain. Previous work has shown that in mice, NT-I7 dramatically increases tumor-infiltrating CD8+ T cells while reducing the frequency of PD-1+ CD8+ T cells in the tumor. There is also significant expansion of Central Memory (CM)-phenotype CD8+ T cells (CD62L+CD44+) in the tumor and tumor draining lymph node. Here, we investigated the anti-tumor effect of NT-I7 in combination with a T cell activator, SLC-3010 (hIL-2/TCB2c complex), in MC38 tumor-bearing mice. Because TCB2 is an antibody specific for IL-2 that blocks interaction of IL-2 and IL-2Rα (CD25), SLC-3010 can selectively activate T cells while disfavoring Treg activation. Mice were administered a single dose of NT-I7 or SLC-3010 via intramuscular or intravenous injection, respectively. The combination of NT-I7 with SLC-3010 enhanced the anti-tumor response with increased number and frequency of CD8+ T cells as well as granzyme B expression in the tumor. The number of CD8+ T cells peaked at day 4 and day 7 by SLC-3010 and NT-I7, respectively. The number of Tregs in the tumor was slightly increased by NT-I7 and SLC-3010, but it was not statistically significant. Interestingly, NT-I7, but not SLC-3010, increased the frequency of PD-1+TCF-1+TOX- stem-like CD8+ T cells in the draining lymph node. Meanwhile, SLC-3010 significantly increased the number of PD-1+ CD8+ T cells in the tumor. Our data suggests that NT-I7 can be applied in combination with other immunotherapies such as IL-2 to enhance the anti-tumor response. Citation Format: Seungtae Baek, Sun-Kyoung Im, Minji Lee, Mankyu Ji, Miyoung Kim, Daeun Kim, Jun Young Lee, Donghoon Choi. rhIL-7-hyFc (efineptakinalpha; NT-I7) enhances the anti-tumor response when combined with hIL-2/TCB2c complex [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 4199.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 4199
Open AccessAbstract 4199: rhIL-7-hyFc (efineptakinalpha; NT-I7) enhances the anti-tumor response when combined with hIL-2/TCB2c complex
RhIL-7-hyFc (efineptakin-alfa; NT-I7) is a potent T cell amplifier, with a homodimeric interleukin-7 (IL-7) fused to the hybridizing IgD/IgG4 immunoglobulin domain. Previous work has shown that in mice, NT-I7 dramatically increases tumor-infiltrating CD8+ T cells while reducing the frequency of PD-1+ CD8+ T cells in the tumor. There is also significant expansion of Central Memory (CM)-phenotype CD8+ T cells (CD62L+CD44+) in the tumor and tumor draining lymph node. Here, we investigated the anti-tumor effect of NT-I7 in combination with a T cell activator, SLC-3010 (hIL-2/TCB2c complex), in MC38 tumor-bearing mice. Because TCB2 is an antibody specific for IL-2 that blocks interaction of IL-2 and IL-2Rα (CD25), SLC-3010 can selectively activate T cells while disfavoring Treg activation. Mice were administered a single dose of NT-I7 or SLC-3010 via intramuscular or intravenous injection, respectively. The combination of NT-I7 with SLC-3010 enhanced the anti-tumor response with increased number and frequency of CD8+ T cells as well as granzyme B expression in the tumor. The number of CD8+ T cells peaked at day 4 and day 7 by SLC-3010 and NT-I7, respectively. The number of Tregs in the tumor was slightly increased by NT-I7 and SLC-3010, but it was not statistically significant. Interestingly, NT-I7, but not SLC-3010, increased the frequency of PD-1+TCF-1+TOX- stem-like CD8+ T cells in the draining lymph node. Meanwhile, SLC-3010 significantly increased the number of PD-1+ CD8+ T cells in the tumor. Our data suggests that NT-I7 can be applied in combination with other immunotherapies such as IL-2 to enhance the anti-tumor response. Citation Format: Seungtae Baek, Sun-Kyoung Im, Minji Lee, Mankyu Ji, Miyoung Kim, Daeun Kim, Jun Young Lee, Donghoon Choi. rhIL-7-hyFc (efineptakinalpha; NT-I7) enhances the anti-tumor response when combined with hIL-2/TCB2c complex [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 4199.
- Open Access
- 1 January 2021
- Published by XMLink in Nutrition Research and Practice
- Vol. 15 (4) , 411-430
Dietary modulation of gut microbiota for the relief of irritable bowel syndrome
Kim MY, et al. Nutr Res Pract. 2021 Aug;15(4):411-430. https://doi.org/10.4162/nrp.2021.15.4.411
- 1 January 2021
- Published by XMLink in Nutrition Research and Practice
- Vol. 15 (4) , 411-430
Open AccessDietary modulation of gut microbiota for the relief of irritable bowel syndrome
Kim MY, et al. Nutr Res Pract. 2021 Aug;15(4):411-430. https://doi.org/10.4162/nrp.2021.15.4.411
- Open Access
- 28 December 2020
- Published by MDPI AG in Applied Sciences
- Vol. 11 (1) , 218
Can Walnut Serve as a Magic Bullet for the Management of Non-Alcoholic Fatty Liver Disease?
Walnut contains many nutrients and bioactive components such as essential fatty acids, polyphenols, fiber, ɤ-tocopherol, folate, minerals, and vegetable protein, and has therefore been regarded as a natural functional food. Walnut-enriched diets have been demonstrated to be useful for heart health, cancer prevention, and metabolic disorders owing to their anti-oxidative and anti-inflammatory properties as well as for the maintenance of a healthy metabolism and immune function. Walnut extracts, either phenolic or lipid, also demonstrated the health effects in animal and cultured cell studies. More recently, the beneficial effects of walnut consumption on non-alcoholic fatty liver disease, which is a hepatic manifestation of obesity, hyperlipidemia, type 2 diabetes mellitus, and metabolic syndrome with substantial hepatic accumulation of triglyceride, have been proposed because walnut and a walnut-containing diet can modulate the etiologic mechanism such as ameliorating systemic and hepatic dyslipidemia, reducing lipotoxicity and inflammation, enhancing immune function, and maintaining gut microbiota balance. Through the extensive literature review we discuss the preventive roles of walnut in the development and progression of non-alcoholic fatty liver disease (NAFLD) and provide mechanistic insights into these effects.
- 28 December 2020
- Published by MDPI AG in Applied Sciences
- Vol. 11 (1) , 218
Open AccessCan Walnut Serve as a Magic Bullet for the Management of Non-Alcoholic Fatty Liver Disease?
Walnut contains many nutrients and bioactive components such as essential fatty acids, polyphenols, fiber, ɤ-tocopherol, folate, minerals, and vegetable protein, and has therefore been regarded as a natural functional food. Walnut-enriched diets have been demonstrated to be useful for heart health, cancer prevention, and metabolic disorders owing to their anti-oxidative and anti-inflammatory properties as well as for the maintenance of a healthy metabolism and immune function. Walnut extracts, either phenolic or lipid, also demonstrated the health effects in animal and cultured cell studies. More recently, the beneficial effects of walnut consumption on non-alcoholic fatty liver disease, which is a hepatic manifestation of obesity, hyperlipidemia, type 2 diabetes mellitus, and metabolic syndrome with substantial hepatic accumulation of triglyceride, have been proposed because walnut and a walnut-containing diet can modulate the etiologic mechanism such as ameliorating systemic and hepatic dyslipidemia, reducing lipotoxicity and inflammation, enhancing immune function, and maintaining gut microbiota balance. Through the extensive literature review we discuss the preventive roles of walnut in the development and progression of non-alcoholic fatty liver disease (NAFLD) and provide mechanistic insights into these effects.
- Open Access
- 1 June 2019
- Published by Elsevier in Molecules and Cells
- Vol. 42 (6) , 448-459
Combination Therapy with a PI3K/mTOR Dual Inhibitor and Chloroquine Enhances Synergistic Apoptotic Cell Death in Epstein–Barr Virus-Infected Gastric Cancer Cells
Mi-Young Kim, Annie J. Kruger, Ju-Yeon Jeong, Jaehee Kim, Phil kyung Shin, Sun Young Kim, Joo Young Cho, Ki Baik Hahm, and Sung Pyo Hong. Mol. Cells 2019;42:448-59. https://doi.org/10.14348/molcells.2019.2395
- 1 June 2019
- Published by Elsevier in Molecules and Cells
- Vol. 42 (6) , 448-459
Open AccessCombination Therapy with a PI3K/mTOR Dual Inhibitor and Chloroquine Enhances Synergistic Apoptotic Cell Death in Epstein–Barr Virus-Infected Gastric Cancer Cells
Mi-Young Kim, Annie J. Kruger, Ju-Yeon Jeong, Jaehee Kim, Phil kyung Shin, Sun Young Kim, Joo Young Cho, Ki Baik Hahm, and Sung Pyo Hong. Mol. Cells 2019;42:448-59. https://doi.org/10.14348/molcells.2019.2395
- 1 April 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 498 (3) , 509-515
ELK3-GATA3 axis modulates MDA-MB-231 metastasis by regulating cell-cell adhesion-related genes
- 1 April 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 498 (3) , 509-515
ELK3-GATA3 axis modulates MDA-MB-231 metastasis by regulating cell-cell adhesion-related genes